www.bioss.com.cn
sales@bioss.com.cn
techsupport@bioss.com.cn
400-901-9800

Recombinant SARS-Cov-2 Spike S1 protein (69/70 deletion, 144Y deletion, N501Y, A570D, D614G, P618H), His (HEK293)

Catalog Number:	bs-41456P
Concentration:	＞0.5 mg/ml
AA Seq:	14-685/1273
Predicted MW:	78.6
Detected MW:	110-130 kDa
Tags:	His
Activity:	Yes
Endotoxin:	Not analyzed
Purity:	>95% as determined by SDS-PAGE
Purification:	AC
Form:	Lyophilized or Liquid
Storage:	10mM TBS (pH7.4). Stored at -70°C or -20°C. Avoid repeated freeze/thaw cycles.
Background:	The SARS-CoV-2 spike (S) protein is the target of vaccine design efforts to end the COVID-19 pandemic. Despite a low mutation rate, isolates with the D614G substitution in the S protein appeared early during the pandemic, and are now the dominant form worldwide. Here, we analyze the D614G mutation in the context of a soluble S ectodomain construct.

VALIDATION IMAGES



Measured by its binding ability in a functional ELISA. Immobilized human ACE2, His-Avi Tag (Cat: bs-46001P) at 2μg/ml (100ul/Well) can bind SARS-CoV-2 Spike S1 (69/70 deletion, 144Y deletion, N501Y, A570D, D614G, P618H), His Tag (Cat: bs-41456P), the EC50 is 131.51ng/ml.



The purity of the protein is greater than 90% as determined by reducing SDS-PAGE.